Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q70209116 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010728.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q70209116 | ||
| 024 | ‡a 0000-0002-4583-9649 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q70209116 | ||
| 100 | 0 | ‡a Maria Jose Lafuente-Monasterio ‡c researcher ‡9 en | |
| 375 | ‡a 2 ‡2 iso5218 | ||
| 400 | 0 | ‡a Maria Jose Lafuente-Monasterio ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis | ||
| 670 | ‡a Author's In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model | ||
| 670 | ‡a Author's Isoxazolopyrimidine-Based Inhibitors of Dihydroorotate Dehydrogenase with Antimalarial Activity | ||
| 670 | ‡a Author's Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria | ||
| 670 | ‡a Author's Setting Our Sights on Infectious Diseases | ||
| 670 | ‡a Author's Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target | ||
| 909 | ‡a (orcid) 0000000245839649 ‡9 1 | ||
| 919 | ‡a validationoftheproteinkinasepfclk3asamultistagecrossspeciesmalarialdrugtarget ‡A Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target ‡9 1 | ||
| 919 | ‡a settingoursightsoninfectiousdiseases ‡A Setting Our Sights on Infectious Diseases ‡9 1 | ||
| 919 | ‡a leadoptimizationofapyrrolebaseddihydroorotatedehydrogenaseinhibitorseriesforthetreatmentofmalaria ‡A Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria ‡9 1 | ||
| 919 | ‡a isoxazolopyrimidinebasedinhibitorsofdihydroorotatedehydrogenasewithantimalarialactivity ‡A Isoxazolopyrimidine-Based Inhibitors of Dihydroorotate Dehydrogenase with Antimalarial Activity ‡9 1 | ||
| 919 | ‡a essentialbutnotvulnerableindazolesulfonamidestargetinginosinemonophosphatedehydrogenaseaspotentialleadsagainstmycobacteriumtuberculosis ‡A Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis ‡9 1 | ||
| 919 | ‡a invitroselectionpredictsmalariaparasiteresistancetodihydroorotatedehydrogenaseinhibitorsinamouseinfectionmodel ‡A In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model ‡9 1 | ||
| 946 | ‡a a ‡9 1 | ||
| 996 | ‡2 DNB|105751361X | ||
| 996 | ‡2 ISNI|0000000401500584 | ||
| 996 | ‡2 NTA|364407964 | ||
| 996 | ‡2 ISNI|0000000048217453 | ||
| 996 | ‡2 NTA|067959520 | ||
| 996 | ‡2 DNB|1057513571 | ||
| 996 | ‡2 LC|n 2011204045 | ||
| 996 | ‡2 DNB|118440853X | ||
| 996 | ‡2 BNE|XX6525508 | ||
| 996 | ‡2 BNF|11887170 | ||
| 996 | ‡2 BNC|981061086755906706 | ||
| 996 | ‡2 BNE|XX5116145 | ||
| 996 | ‡2 DNB|1057321362 | ||
| 996 | ‡2 RERO|A003659540 | ||
| 996 | ‡2 LC|n 78091678 | ||
| 996 | ‡2 CAOONL|ncf11278345 | ||
| 996 | ‡2 J9U|987007266117605171 | ||
| 996 | ‡2 BNE|XX878473 | ||
| 996 | ‡2 BNE|XX1525320 | ||
| 996 | ‡2 ISNI|0000000042733916 | ||
| 996 | ‡2 ISNI|000000037947610X | ||
| 996 | ‡2 BNF|17140429 | ||
| 996 | ‡2 DNB|1065263910 | ||
| 996 | ‡2 ISNI|0000000074461652 | ||
| 996 | ‡2 BNE|XX1289499 | ||
| 996 | ‡2 LC|no2013021246 | ||
| 996 | ‡2 ISNI|0000000081271646 | ||
| 996 | ‡2 CAOONL|ncf10448417 | ||
| 996 | ‡2 LC|no2004056103 | ||
| 996 | ‡2 LC|no2004056101 | ||
| 996 | ‡2 B2Q|0000407230 | ||
| 996 | ‡2 SUDOC|026666715 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
